NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2061210007

Registered date:28/05/2021

A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)

Basic Information

Recruitment status Complete
Health condition(s) or Problem(s) studiedTakayasu Arteritis
Date of first enrollment13/10/2021
Target sample size50
Countries of recruitment
Study typeInterventional
Intervention(s)Ustekinumab Participants will receive IV infusion and SC injection of ustekinumab. Placebo Participants will receive IV infusion and SC injection of matching placebo. Glucorticoid Taper Regimen Glucocorticoid will be administered orally.

Outcome(s)

Primary OutcomeTime to Relapse Through the End of Double-blind (DB) Period Up to occurrence of 35 events (Up to 24 months) Time to relapse is defined as the assessment of 'signs of relapse present' as judged by the investigator for at least 2 of 5 categories: objective systemic symptoms, subjective systemic symptoms, elevated inflammation markers, vascular signs and symptoms, or ischemic symptoms.
Secondary OutcomeNumber of Participants with Treatment Emergent Adverse Events (TEAEs) Up to 3 years An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. Number of Participants with TEAEs by System Organ Class (SOC) with a Frequency Threshold of 5 Percent (%) or More Up to 3 years An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. Number of Participants with Treatment-emergent Serious Adverse Events (SAEs) Up to 3 years SAE is any untoward medical occurrence that at any dose may results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. Treatment-emergent SAEs are defined as SAEs with onset or worsening on or after date of first dose of study treatment. Time to Relapse of TAK by Kerr's Criteria Through the End of DB Period Up to occurrence of 35 events (Up to 24 months) Time to relapse is defined as the assessment of 'signs of relapse present' as judged by the investigator for at least 2 of 4 categories: systemic symptoms (objective or subjective), elevated inflammation markers, vascular signs, and symptoms and ischemic symptoms. Time to Relapse Based on Clinical Symptoms Through the End of DB Period Up to occurrence of 35 events (Up to 24 months) Time to relapse based on clinical symptoms through the end of DB period will be reported. Participants who meet at least 1 category in the following 4 clinical categories will be considered as relapse per clinical symptom: 1) Objective systemic symptoms; 2) Subjective systemic symptoms; 3) Vascular signs and symptoms; 4) Ischemic symptoms. Time to Relapse of TAK in Each of the 5 Categories Through the End of DB Period Up to occurrence of 35 events (Up to 24 months) Time to relapse is defined as the assessment of 'signs of relapse present' as judged by the investigator in each of the 5 categories: objective systemic symptoms, subjective systemic symptoms, elevated inflammation markers, vascular signs and symptoms, or ischemic symptoms. Percentage of Participants with Relapse in Each of the 5 Categories Through the End of DB Period Up to occurrence of 35 events (Up to 24 months) Percentage of participants with relapse in each of the 5 categories (objective systemic symptoms, subjective systemic symptoms, elevated inflammation markers, vascular signs and symptoms, or ischemic symptoms) through the end of DB period will be reported. Cumulative Oral Glucocorticoid (GC) Dose Through the End of DB Period Up to occurrence of 35 events (Up to 24 months) Cumulative oral GC dose (prednisolone or equivalent) through the end of DB period will be reported. Change from Baseline in Oral GC Dose Through the End of DB Period Baseline; up to the end of DB period (Up to 24 months) Change from baseline in oral GC dose (prednisolone or equivalent) through the end of DB period will be reported. Number of Participants Achieving GC Dose of 5 milligrams (mg)/day or Less Through the End of DB Period Up to 24 months Number of participants achieving GC dose of 5 mg/day or less at the end of DB period will be reported. Number of Participants with Change from Baseline in Imaging Evaluation Through the End of DB Period Baseline, every 24 weeks from Week 0 and relapse confirmation visit (Up to 24 months) Number of participants with change from baseline in imaging evaluation through the end of DB period will be reported. Vessel involvement such as stenosis, obstruction, and aneurysm; arterial wall thickness; and the presence of mural contrast enhancement and oedema will be assessed for imaging evaluation using magnetic resonance angiography (MRA). Change from Baseline in C-reactive Protein (CRP) Through the End of DB Period Baseline; up to 24 months Change from baseline in CRP through the end of DB period will be reported. Change from Baseline in Erythrocyte Sedimentation Rate (ESR) Through the End of DB Period Baseline; up to 24 months Change from baseline in ESR through the end of DB period will be reported. Serum Concentrations of Ustekinumab Up to end of study (Up to 3 years) Serum concentrations of ustekinumab will be reported. Number of Participants with Positive Anti-ustekinumab Antibodies Up to end of study (Up to 3 years) Number of participants with positive anti-ustekinumab antibodies will be reported.

Key inclusion & exclusion criteria

Age minimum>= 15age old
Age maximum<= 75age old
GenderBoth
Include criteriaInclusion Criteria: - Must have developed a relapse of Takayasu Arteritis (TAK) within 12 weeks prior to administration of study intervention and the relapse must have occurred at a dose of at least 7.5 milligrams (mg)/day (prednisolone or equivalent) - Must be receiving oral glucorticoid (GC) treatment of greater than or equal to (>=)15 mg/day (prednisolone or equivalent), inclusive for the treatment of relapsing TAK and be on a stable dose for at least 2 weeks prior to the first administration of study intervention - If receiving an oral anti-platelet therapy (including but not limited to aspirin, clopidogrel, ticlopidine) or anti-coagulation therapy (including but not limited to warfarin) for treatment of TAK, the dose must have been stable for at least 2 weeks prior to first administration of the study intervention. In terms of warfarin, the dose should be controlled 1-5mg/day to maintain Prothrombin Time and International Normalized Ratio (PT-INR) target range between 2.0-3.0 (if participants are over 70 years old, PT-INR target range should be between 1.6-2.6) - Have no history of latent or active Tuberculosis (TB) prior to screening. An exception is made for participants who have a history of latent TB and are currently receiving treatment for latent TB, will initiate treatment for latent TB at least 3 weeks prior to the first administration of the study intervention, or have documentation of having completed appropriate treatment for latent TB within 3 years prior to the first administration of the study intervention. It is the responsibility of the investigator to verify the adequacy of previous antituberculous treatment and provide appropriate documentation - If receiving an oral anti-hypertensive therapy for treatment of TAK, the dose must have been stable for at least 2 weeks prior to first administration of the study intervention
Exclude criteriaExclusion Criteria: - Has currently any known severe or uncontrolled TAK complications (example, hypertension not responding to adequate treatment, aortic incompetence with cardiac insufficiency, progressing aortic aneurysm, coronary artery lesions with severe stenosis) - Has received immunosuppressant (s) (including but not limited to Methotrexate [MTX], Azathioprine [AZA], Mycophenolate Mofetil [MMF],oral Triamcinolone [TAC], oral Cyclosporine A) within 4 weeks of first study intervention - Has had a Bacille Calmette-guerin (BCG) vaccination within 12 months of screening - Any major illness/condition or evidence of an unstable clinical condition example, history of liver or renal insufficiency (estimated creatinine clearance below 60 milliliters/minute [mL/min]); significant (cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances), disease of any organ system or active acute or chronic infection/infectious illness that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study - Having a condition that is steroid dependent (example, steroid dependent asthma, chronic obstructive pulmonary disease, et cetera) that is not amenable to tapering oral GC

Related Information

Contact

Public contact
Name Medical Information Center
Address 3-5-2 Nishi-kanda, Chiyoda-ku, Tokyo Tokyo Japan 101-0065
Telephone +81-120-183-275
E-mail DL-JANJP-JCO_TL_TSG_EMP@its.jnj.com
Affiliation Janssen Pharmaceutical K.K.
Scientific contact
Name Kazuko Nishikawa
Address 3-5-2 Nishi-kanda, Chiyoda-ku, Tokyo Tokyo Japan 101-0065
Telephone +81-120-183-275
E-mail DL-JANJP-JCO_TL_TSG_EMP@its.jnj.com
Affiliation Janssen Pharmaceutical K.K.